Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Regulation

Trio of approvals includes Seattle Genetics’ breast cancer therapy

Incyte’s Pemazyre pemigatinib approved for cholangiocarcinoma; Everest gains first approval via Singapore

April 18, 2020 1:32 AM UTC

Just two months after granting Priority Review to Seattle Genetics’ Tukysa tucatinib, FDA approved the drug as part of a triple combo to treat breast cancer, marking one of a trio of approvals Friday.

Incyte and Everest also announced approvals. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article